4 Pharma Stocks Heating Up On Wednesday (12/26/18)
CORAL GABLES, FL/ ACCESSWIRE / December 26,2018 / The pharmaceutical industry, like other healthcare related fields, is predicated on the idea that we can do better, in terms of quality of treatment made available to consumers as well as medical technologies created to deliver said treatments. In a world where new diseases are discovered every single day, companies must work even faster to develop new approaches to medical care that satisfy all the needs of patients requiring treatment. Premier Health Group (PHGRF) (PHGI), ArQule, Inc (ARQL), Amarin Corporation plc (AMRN), and AVEO Pharmaceuticals, Inc (AVEO) are 4 pharma stocks that may be worth keeping tabs on this week.
Premier Health Group (PHGRF) (PHGI) is a company determined to improve the quality of care currently made available to consumers in the primary healthcare space. As an industry leader, the Company is focused on developing proprietary technologies to develop healthcare through a network of interconnected primary care clinics by way of artificial intelligence integration and telemedical advancements.
Last week, Premier Health Group (PHGRF) (PHGI) announced that it had signed into a binding letter of intent (LOI) agreement to acquire all outstandingsecures of Cloud Practice Inc.
Following this announcement, Dr. Essam Hamza, chief executive officer of Premier Health said: "We are ecstatic at the opportunity to build on our patient-centric technology platform through the integration of Cloud Practice's suite of software solutions. They have a strong team of developers who are just as enthusiastic as we are about the future of healthcare. We believe that this partnership will help facilitate our vision of integrating telemedicine, online booking, and other premium services with our electronic medical record (EMR) system."
For More Information On Premier Health Group, Click Here
ArQule, Inc. (ARQL) announced earlier this month that the Company had been selected for inclusion in the NASDAQ Biotechnology Index, which effective prior to market open on Christmas Eve.
In recognition of being included on such a major index, the Company's chief operating officer shared his thoughts in an official press release: "Inclusion in the NBI reflects ArQule's clinical progress and heightened investor awareness throughout 2018," said Peter Lawrence, Presidentand Chief Operating Officer at ArQule. "We remain focused on rapidly advancing our pipeline of precision therapeutics for oncology and rare diseases and look forward to a number of data inflection points during 2019."
For More Information On ArQule, Inc, Click Here
Amarin Corporation plc (AMRN) saw its company stock climb 9.83% to $13.63 per share in midday trading on Wednesday afternoon. The Company's share increase may be a result of momentum catalyzed from a November announcement that it had registered an underwritten public offering of its American Depository Shares (ADSs). According to the press release issued at the time, all of the shares in the proposed offering were to be sold by Amarin. The offering was subject to market conditions, and there could be no assurance as to whether or when theyoffering might be completed.
Per the press release, the Company shared that, following the completion of the offering, it intends to use the net proceeds from the offering to support the ongoing commercialization of Vascepa following REDUCE-IT results, including seeking regulatory approval to expand the approved label for Vascepa based on the cardioprotectiveaffect of the drug demonstrated in its most recent study.
For More Information on Amarin Corporation plc, Click Here
AVEO Pharmaceuticals, Inc (AVEO) announced, earlier this month, that it had entered into a clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca's IMFINZI®, a human monoclonal antibody directed against death-ligand 1, in combination with several other drugs to hopefully provide new treatment options for those suffering from liver cancer.
Per the official press release, AVEO will serve as the study sponsor, with study costs shared equally by both parties and clinical drug supplied by each respective company.
"We are thrilled to collaborate with AstraZeneca to explore another tivozanib-immunotherapy combination and look forward to understanding the potential of combining tivozanib withdurvalumab in liver cancer," said Michael Bailey, presidentand chief executive officer of AVEO.
For More Information On AVEO Pharmaceuticals, Inc, Click Here
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We were paid an additional $100,000 (CASH) for continued coverage. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6)Six month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
Contact Information:
SOURCE: StockPrice.com
